A highly potent and stable pan-coronavirus fusion inhibitor as a candidate prophylactic and therapeutic for COVID-19 and other coronavirus diseases
Jie Zhou(Fudan University), Qian Wang(Shanghai Medical College of Fudan University), Wei Xu(Beijing Geriatric Hospital), Zezhong Liu(Ministry of Education), Qiaoshuai Lan(Chinese University of Hong Kong), Shibo Jiang(Shanghai Medical College of Fudan University), Shuai Xia(Shanghai Medical College of Fudan University), Shan Su(New York Blood Center), Lu Lu(Shanghai Medical College of Fudan University), Chao Wang, Youhua Xie(Shanghai Medical College of Fudan University), Yanxing Cai(Fudan University), Lixiao Xing(Fudan University), Jing Pu(University of New Mexico)
Cited by 37
Related Papers
Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion
|Cell Research|2020|1.4k
Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein
|Cellular and Molecular Immunology|2020|759
Attenuated replication and pathogenicity of SARS-CoV-2 B.1.1.529 Omicron
|RePEc: Research Papers in Economics|0|647
Mechanisms and functions of lysosome positioning
|Journal of Cell Science|2016|568
Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor
|Nature Communications|2014|400